Why Novo Nordisk Stock Just Slipped
Investors may get a second bite at the apple, and a second chance to buy this GLP-1 drug leader at a discount price.
Novo Nordisk (NYSE: NVO) stock tumbled 3.9% through 10:45 a.m. ET this morning after the manufacturer of GLP-1 weight loss drugs announced its CEO, Lars Fruergaard Jørgensen, will step down from his role as CEO in "mutual agreement" with the company's board.
Jørgensen will be allowed to "continue as CEO for a period to support a smooth transition to new leadership."
Which means the company hasn't yet found a new CEO.
